drugset / Trial / NCT04474405

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

NCT04474405

Phase 0 Completed 36 enrolled Avid Radiopharmaceuticals
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This early phase 1 study explored the brain uptake, retention, and safety of flortaucipir and obtained preliminary information regarding dosimetry of flortaucipir.

Timeline

Start
2013-08-16
Primary completion
2013-12-09
Completion
2013-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Flortaucipir F18 Diagnostic / imaging agent 370 mbq Intravenous
Background florbetapir F 18 Diagnostic / imaging agent 370 mbq Intravenous

Indications